Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE To assess the costs and project the potential lifetime cost-effectiveness of the ongoing Autoimmunity Screening for Kids (ASK) program, a large-scale, presymptomatic type 1 diabetes screening program for children and adolescents in the metropolitan Denver region. RESEARCH DESIGN AND METHODS We report the resource utilization, costs, and effectiveness measures from the ongoing ASK program compared with usual care (i.e., no screening). Additionally, we report a practical screening scenario by including utilization and costs relevant to routine screening in clinical practice. Finally, we project the potential cost-effectiveness of ASK and routine screening by identifying clinical benchmarks (i.e., diabetic ketoacidosis [DKA] events avoided, HbA1c improvements vs. no screening) needed to meet value thresholds of $50,000–$150,000 per quality-adjusted life-year (QALY) gained over a lifetime horizon. RESULTS Cost per case detected was $4,700 for ASK screening and $14,000 for routine screening. To achieve value thresholds of $50,000–$150,000 per QALY gained, screening costs would need to be offset by cost savings through 20% reductions in DKA events at diagnosis in addition to 0.1% (1.1 mmol/mol) improvements in HbA1c over a lifetime compared with no screening for patients who develop type 1 diabetes. Value thresholds were not met from avoiding DKA events alone in either scenario. CONCLUSIONS Presymptomatic type 1 diabetes screening may be cost-effective in areas with a high prevalence of DKA and an infrastructure facilitating screening and monitoring if the benefits of avoiding DKA events and improved HbA1c persist over long-run time horizons. As more data are collected from ASK, the model will be updated with direct evidence on screening effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple studies indicate that measuring islet autoantibodies in relatives of those with type 1 diabetes (47) or in children from the general population (72,73) can effectively identify those who will develop type 1 diabetes.”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple studies indicate that measuring islet autoantibodies in relatives of those with type 1 diabetes (45), in children from the general population (71,72), or in children from the general population with high genetic risk (73) can identify many individuals who will develop type 1 diabetes.”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60568-7 · Cited by 1,854
Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012
Mayer-Davis, E. J., Lawrence, J. M., Dabelea, D., Divers, J., Isom, S., Dolan, L., Imperatore, G., Linder, B., Marcovina, S., Pettitt, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1610187 · Cited by 1,476
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Self-citationInsel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Self-citationAn anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.193 · Cited by 653
Yu, L., Robles, D. T., Abiru, N., Kaur, P., Rewers, M., Kelemen, K., & Eisenbarth, G. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556697 · Cited by 450
Self-citationde Boer, I. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.16 · Cited by 351
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion
Martin, C. L., Albers, J., Herman, W. H., Cleary, P., Waberski, B., Greene, D. A., Stevens, M. J., & Feldman, E. L. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1549 · Cited by 350
Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany
Ziegler, A.-G., Kick, K., Bonifacio, E., Haupt, F., Hippich, M., Dunstheimer, D., Lang, M., Laub, O., Warncke, K., Lange, K., et al. (2020) · JAMA · doi:10.1001/jama.2019.21565 · Cited by 312
Steck, A. K., & Rewers, M. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148221 · Cited by 310
Self-citationRewers, A., Klingensmith, G., Davis, C., Petitti, D. B., Pihoker, C., Rodriguez, B., Schwartz, I. D., Imperatore, G., Williams, D., Dolan, L. M., et al. (2008) · Pediatrics · doi:10.1542/peds.2007-1105 · Cited by 298
Bonifacio, E., Yu, L., Williams, A. K., Eisenbarth, G. S., Bingley, P. J., Marcovina, S. M., Adler, K., Ziegler, A. G., Mueller, P. W., Schatz, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0293 · Cited by 291
Self-citationDiabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control
Duca, L. M., Wang, B., Rewers, M., & Rewers, A. (2017) · Diabetes Care · doi:10.2337/dc17-0558 · Cited by 236
Self-citationBarker, J. M., Goehrig, S. H., Barriga, K., Hoffman, M., Slover, R., Eisenbarth, G. S., Norris, J. M., Klingensmith, G. J., & Rewers, M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1399 · Cited by 220
Self-citationAntiislet autoantibodies usually develop sequentially rather than simultaneously
Yu, L. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.12.4264 · Cited by 214
Self-citationRogers, M. A. M., Kim, C., Banerjee, T., & Lee, J. M. (2017) · BMC Medicine · doi:10.1186/s12916-017-0958-6 · Cited by 208
Elding Larsson, H., Vehik, K., Bell, R., Dabelea, D., Dolan, L., Pihoker, C., Knip, M., Veijola, R., Lindblad, B., Samuelsson, U., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1026 · Cited by 194
Steck, A. K., Vehik, K., Bonifacio, E., Lernmark, A., Ziegler, A.-G., Hagopian, W. A., She, J., Simell, O., Akolkar, B., Krischer, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2426 · Cited by 185
Self-citationDiabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010-2017
Alonso, G. T., Coakley, A., Pyle, L., Manseau, K., Thomas, S., & Rewers, A. (2020) · Diabetes Care · doi:10.2337/dc19-0428 · Cited by 117
Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels
the Danish Society for Diabetes in Childhood and Adolescence, Fredheim, S., Johannesen, J., Johansen, A., Lyngsøe, L., Rida, H., Andersen, M. L. M., Lauridsen, M. H., Hertz, B., Birkebæk, N., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2850-z · Cited by 112
Secular Trends in Incidence of Childhood IDDM in 10 Countries
Diabetes Epidemiology Research International Group (1990) · Diabetes · doi:10.2337/diab.39.7.858 · Cited by 107
Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998-2012
Rewers, A., Dong, F., Slover, R. H., Klingensmith, G. J., & Rewers, M. (2015) · JAMA · doi:10.1001/jama.2015.1414 · Cited by 92
Self-citationHekkala, A. M., Ilonen, J., Toppari, J., Knip, M., & Veijola, R. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12541 · Cited by 79
Ketoacidosis at onset of type 1 diabetes is a predictor of long-term glycemic control
Shalitin, S., Fisher, S., Yackobovitch‐Gavan, M., de Vries, L., Lazar, L., Lebenthal, Y., & Phillip, M. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12546 · Cited by 69
Institute for Clinical and Economic Review
Peter J., N., Joshua T., C., & Daniel A, O. (2021) · The Right Price · doi:10.1093/oso/9780197512883.003.0006 · Cited by 60
Screening for T1D risk to reduce DKA is not economically viable
Meehan, C., Fout, B. T., Ashcraft, J., Schatz, D., & Haller, M. J. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12313 · Cited by 51
Shalitin, S., & Phillip, M. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0321-x · Cited by 45
Late-onset islet autoimmunity in childhood: the Diabetes Autoimmunity Study in the Young (DAISY)
Frohnert, B. I., Ide, L. M., Dong, F., Barón, A. E., Steck, A. K., Norris, J. M., & Rewers, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4256-9 · Cited by 38
Self-citationAssociation Between Glycated Hemoglobin and Health Utility for Type 1 Diabetes
McQueen, R. B., Ellis, S. L., Maahs, D. M., Anderson, H. D., Nair, K. V., Libby, A. M., & Campbell, J. D. (2014) · Patient · doi:10.1007/s40271-014-0045-4 · Cited by 18
Self-citationMcQueen, R. B., Breton, M. D., Ott, M., Koa, H., Beamer, B., & Campbell, J. D. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815599551 · Cited by 17
Self-citationMcQueen, R. B., Breton, M. D., Craig, J., Holmes, H., Whittington, M. D., Ott, M. A., & Campbell, J. D. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818769098 · Cited by 12
Self-citation
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Metadata
- Authors
- McQueen, R. B., Geno Rasmussen, C., Waugh, K., Frohnert, B. I., Steck, A. K., Yu, L., Baxter, J., & Rewers, M.
- Affiliations
- University of Colorado Anschutz (US)
- Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO
- Corresponding author
- McQueen, R. Brett
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-04-23
- Volume
- 43
- Issue
- 7
- Pages
- 1496-1503
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7305000
- OpenAlex
- W3018568543
- Cited by
- 138
- References
- 35
- Citations by year
- 2026: 26 · 2025: 28 · 2024: 23 · 2023: 14 · 2022: 21 · 2021: 23 · 2020: 3
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- JDRF
- The Leona M. and Harry B. Helmsley Charitable Trust
- Janssen Research and Development
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 1 diabetes, presymptomatic screening, cost-effectiveness, diabetic ketoacidosis, HbA1c, children and adolescents, quality-adjusted life years, screening costs
- MeSH terms
- Adolescent, Autoantibodies, Child, Child, Preschool, Colorado, Cost-Benefit Analysis, Costs and Cost Analysis, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Mass Screening, Diabetic Ketoacidosis, Health Care Costs, Quality-Adjusted Life Years, Early Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.